Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 4/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.38 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.38 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GRIK5 | Q16478 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | TYMP | P19971 | 8/20 | 0.37 |
| ▸ | PYGM | P11217 | 1/20 | 0.34 |
| ▸ | DPYD | Q12882 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL65891 | 0.78 | TDP1 (0.53) | CYP1A2GRIA1GRIA2GRIA4KMT2A | |
| SCHEMBL2929916 | 0.76 | GRIA1 (0.38) | CYP1A2GRIA1GRIA2GRIA4BLM | |
| SCHEMBL19841638 | 0.70 | KMT2A (0.42) | TK1CYP1A2GRIA1GRIA2GRIA4 | |
| SCHEMBL9332865 | 0.69 | TK1 (0.40) | TK1CYP1A2KMT2ATYMPTDP1 | |
| SCHEMBL10939258 | 0.68 | DPYD (0.41) | TK1CYP1A2GRIA1GRIA2GRIA4 | |
| SCHEMBL4379055 | 0.68 | DAO (0.43) | TK1CYP1A2GRIA1GRIA2GRIA4 | |
| SCHEMBL12747301 | 0.64 | CYP1A2 (0.41) | TK1CYP1A2GRIA1GRIA2GRIA4 | |
| SCHEMBL8561169 | 0.63 | TYMP (0.38) | TK1CYP1A2GRIA1GRIA2GRIA4 | |
| SCHEMBL7204552 | 0.63 | CRBN (0.48) | — | |
| SCHEMBL9310440 | 0.62 | TK1 (0.56) | TK1CYP1A2GRIA1GRIA2GRIA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110245479-A1 | Method for Generating Aptamers with Improved Off-Rates | SOMALOGIC, INC. (US) | 2011-10-06 | — | — | US | claimed |
| EP-2069529-A2 | METHOD FOR GENERATING APTAMERS WITH IMPROVED OFF-RATES | Somalogic, Inc. (US) | 2009-06-17 | — | — | EP | claimed |
| WO-2009012418-A2 | METHOD FOR GENERATING APTAMERS WITH IMPROVED OFF-RATES | SOMALOGIC, INC. (US) | 2009-01-22 | — | — | WO | claimed |
| US-20090004667-A1 | METHOD FOR GENERATING APTAMERS WITH IMPROVED OFF-RATES | SOMALOGIC, INC. (US) | 2009-01-01 | — | — | US | claimed |
| EP-1994171-A2 | MULTIPLEXED ANALYSES OF TEST SAMPLES | SomaLogic, Inc. (US) | 2008-11-26 | — | — | EP | claimed |
| EP-1889910-A2 | Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex | SomaLogic, Inc. (US) | 2008-02-20 | — | — | EP | claimed |
| EP-0736105-B1 | SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT: PHOTOSELECTION OF NUCLEIC ACID LIGANDS | SOMALOGIC INC (US) | 2007-11-21 | — | — | EP | claimed |
| WO-2007084886-A2 | MULTIPLEXED ANALYSES OF TEST SAMPLES | SOMALOGIC, INCORPORATED (US) | 2007-07-26 | — | — | WO | claimed |
| US-20070166740-A1 | MULTIPLEXED ANALYSES OF TEST SAMPLES | SOMALOGIC, INCORPORATED (US) | 2007-07-19 | — | — | US | claimed |
| US-20070166741-A1 | MULTIPLEXED ANALYSES OF TEST SAMPLES | SOMALOGIC, INCORPORATED (US) | 2007-07-19 | — | — | US | claimed |
| US-20040132067-A1 | Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex | SOMALOGIC, INC. | 2004-07-08 | — | — | US | claimed |
| US-20030054360-A1 | Method and apparatus for the automated generation of nucleic acid ligands | SOMALOGIC, INC. | 2003-03-20 | — | — | US | claimed |
| US-6482594-B2 | Made by exposing nucleic acid candidate sequences having photoreactive groups to the target molecule, irradiating complexes formed to crosslink, and separating the crosslinked complexes and amplifying to give the ligands | SOMALOGIC, INC. | 2002-11-19 | — | — | US | claimed |
| WO-2002077262-A2 | METHOD AND APPARATUS FOR THE AUTOMATED GENERATION OF NUCLEIC ACID LIGANDS | SOMALOGIC, INC. (US) | 2002-10-03 | — | — | WO | claimed |
| US-20020106652-A1 | Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex | SOMALOGIC, INC. | 2002-08-08 | — | — | US | claimed |
| US-6001577-A | SCREENING FOR LIGANDS ASSOCIATED WITH A DISEASE BY DETECTING LIGAND THAT PHOTOCROSSLINKS TO TARGET WITH PHOTOREACTIVE GROUPS FROM CANDIDATE MIXTURE, REMOVING ANY NUCLEIC ACIDS WITH AFFINITIES NOT ASSOCIATED WITH DISEASE, AND AMPLIFYING | NEXSTAR PHARMACEUTICALS, INC. (US) | 1999-12-14 | — | — | US | claimed |
| EP-0736105-A4 | SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT: PHOTOSELECTION OF NUCLEIC ACID LIGANDS AND SOLUTION SELEX | UNIV RESEARCH CORP (US) | 1998-10-28 | — | — | EP | claimed |
| US-5763177-A | SELEX IS AN ACRONYM FOR SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT; USEFUL FOR DIAGNOSIS AND/OR TREATMENT OF DISEASES OR PATHOLOGICAL OR TOXIC STATES | NEXSTAR PHARMACEUTICALS, INC. (US) | 1998-06-09 | — | — | US | claimed |
| EP-0736105-A1 | SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT: PHOTOSELECTION OF NUCLEIC ACID LIGANDS AND SOLUTION SELEX | NeXstar Pharmaceuticals, Inc. (US) | 1996-10-09 | — | — | EP | claimed |
| WO-1995008003-A1 | SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT: PHOTOSELECTION OF NUCLEIC ACID LIGANDS AND SOLUTION SELEX | UNIVERSITY RESEARCH CORPORATION (US) | 1995-03-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245479-A1 | Method for Generating Aptamers with Improved Off-Rates | DDX1, DDX3X, DDX18 | TK1 214/4885CYP1A2 4052/4885GRIA1 2064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.